Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults.
Rahul S DadwaniWen WanM Reza SkandariElbert S HuangPublished in: MDM policy & practice (2023)
On average, older adults benefit significantly from SGLT2I and GLP1RA use. However, the benefits of these drugs are not clinically significant among older patients with life expectancy less than 4 y.There is potential harm in injectable GLP1RA use in the oldest categories of adults with type 2 diabetes.Heterogeneity in life expectancy and patient preferences for injectable versus oral medications are important to consider when prescribing newer diabetes medications.
Keyphrases
- rheumatoid arthritis
- physical activity
- healthcare
- type diabetes
- public health
- disease activity
- primary care
- hyaluronic acid
- cardiovascular disease
- case report
- mental health
- ankylosing spondylitis
- tissue engineering
- single cell
- human health
- interstitial lung disease
- glycemic control
- emergency department
- systemic lupus erythematosus
- metabolic syndrome
- systemic sclerosis
- health promotion
- electronic health record